key: cord-0329430-tekd0x5v
authors: Mengual, L.; Frantzi, M.; Mokou, M.; Ingelmo-Torres, M.; Vlaming, M.; Merseburger, A. S.; Roesch, M. C.; Culig, Z.; Alcaraz, A.; Vlahou, A.; Mischak, H.; Van der Heijden, A. G.
title: A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring
date: 2021-12-15
journal: nan
DOI: 10.1101/2021.12.15.21267846
sha: 285f79497e27bd92086cfc4f06e6dac507bfc5e6
doc_id: 329430
cord_uid: tekd0x5v

Purpose: Non-invasive urine-based biomarkers for bladder cancer (BC) diagnosis and surveillance can potentially improve current diagnostic and monitoring protocols by guiding cystoscopy. Here, we aim to access the diagnostic performance of nomograms based on published biomarker panels for BC detection (BC-116) and monitoring of recurrence (BC-106) in combination with cytology, in two prospectively collected patient cohorts. Experimental Design: 602 recruited patients were screened for presence of BC, out of which 551 were found eligible for further analysis. For the primary setting, urine samples from 73 eligible patients were analyzed from those diagnosed with primary BC (n=27) and benign urological disorders (n=46). For the surveillance setting, 478 eligible patients were considered (83 BC recurrences; 395 negative for recurrence). Urine samples were analyzed with capillary electrophoresis coupled to mass spectrometry and the biomarker score was estimated via a support vector machine-based software. Results: Validation of the BC-116 biomarker panel resulted in 89% sensitivity and 67% specificity (AUCBC-116=0.82), similar to the published estimates. The nomogram based on cytology and BC-116 resulted in good (AUCNom116=0.85) but not significantly better performance than the BC-116 alone (P=0.5672). BC-106 biomarker panel showed 89% sensitivity and 32% specificity for surveillance, while improved performance was achieved when a nomogram including BC-106 and cytology was evaluated (AUCNom106=0.82), significantly outperforming both cytology (AUCcyt=0.72;P=0.0022) and BC-106 alone (AUCBC-106=0.67;P=0.0012). Conclusions: BC-116 biomarker panel is a useful test for detecting primary BC. BC-106 classifier integrated with cytology and showing >95% negative predictive value, might be useful for decreasing the number of cystoscopies during surveillance.

Bladder cancer (BC) has the highest recurrence rate of all cancers. The overall lifetime 101 risk for BC is 2.4%. In Europe, the age-standardized incidence and mortality rates for 102 BC are 11.3 and 3.0 per 100,000 person years, respectively (1,2). In the USA, the 103 respective rate is 10.9 per 100,000 person years, while the annual number of 104 attributable deaths is 2.1 per 100,000 persons (2,3). Most incident BC cases (roughly 105 75%) are non-muscle invasive (NMIBC) tumors, exhibiting a 5-year recurrence rate of 106 50-70% and a 10-30% 5-year progression rate to muscle-invasive disease (MIBC), thus 107 necessitating long-term patient monitoring (4). Both the timely detection of primary/ 108 incident BC and efficacious surveillance of BC recurrence are vital for optimal patient 109 outcomes. Cystoscopy remains the gold standard for BC detection (5). However, it is an 110 invasive and expensive approach, having also potential complications while subtle 111 recurrences can be easily missed (6). Furthermore, it is bothersome for patients (7).

During the corona pandemic, increased waiting times for cystoscopies, and delayed 113 diagnoses are more prominent. (14), in 132 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 combination with appropriate bioinformatics tools and algorithms that enable CE-MS 133 data assessment, peptide list extraction and calibration using internal standard peptides 134 (15). Urinary profiling data acquired by CE were further excluded as histopathological data based on transurethral resection of the 180 bladder tumor (TURB-T) or biopsy were either not available or reported a benign lesion. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Table   209 1 and the full list of patient clinical data is given in Supplementary Table S1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10. 1101 /2021 were advised to have cytology at cystoscopy or during the period between cystoscopy 233 and surgery. Urine cytology was performed according to Papanicolaou staining and 234 evaluated by expert pathologists in each center blinded to the patient's clinical history.

The results were considered as positive or negative. 238 Urine sample preparation and CE-MS analysis was performed according to previous 239 reports (19, 20, 24) . In brief, 700 µl of each urine sample were diluted with two volumes 240 alkaline buffer containing 2 M urea, 10 mM NH 4 OH and 0.02% SDS (pH 10.5). The proportion, mean, standard deviation, median and interquartile range (25th-75th 261 percentiles) estimates were calculated to describe the distribution of the different 262 variables in the patients' cohorts (summarized in Table 1 ). The biomarker panels' 263 scores were calculated via the support vector machine (SVM)-based software, namely 264 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. controls were misclassified as BC cases. Considering a prevalence rate of 37%, as 284 estimated on the basis of the participating centers, the NPV was computed at 91% 285 (95% CI 61% to 100%) while the PPV was estimated at 61% (95% CI 33% to 85%). As 286 presented in Figure 2B , the BC-116 biomarker panel significantly discriminated Table 1 ). Sensitivity of cytology for 294 detecting primary BC was estimated at 42.3% while sensitivity of the classifier was 295 88.5% in this subset of patients. Twelve of the 26 primary BC cases were detected by 296 the BC-116 biomarker panel but were missed by urine cytology. Notably, out of these 12 297 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 311 An integrated nomogram based on the BC-116 based urinary biomarker panel and 312 cytology was also examined in the primary patient cohort. As shown in Figure 3B , the 313 AUC for the integrative nomogram was estimated 0.85 (0.73-0.93; 95% CI; P< 0.0001) 314 only slightly but not significantly higher than the BC-116 alone (0.84; P= 0.5672) yet 315 significantly higher than cytology alone (0.68; P= 0.0016). At the optimal cut-off level of 316 0.39, the sensitivity was estimated at 84.6% and the specificity at 75%. The integrative 317 nomogram correctly classified 23 out of the 26 primary BC cases whereas 9 out of the 318 32 controls were misclassified. Considering a prevalence rate of 37%, as estimated on 319 the basis of the participating centers, the NPV was computed at 89.5% (95% CI 60% to 320 99%) while PPV was estimated at 66.6% (95% CI 35% to 90%). 323 The performance of the BC-106 biomarker panel for detection of bladder cancer 324 recurrence was evaluated in 478 patients. Among those, were 83 patients bearing a 325 histopathologically confirmed BC recurrence and 395 controls negative for recurrence.

As presented in Figure 4A , the AUC was estimated at 0.67 with the 95% CI ranging However, the number of correctly classified negative controls was only 112. Accounting 331 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 panels demonstrated high NPV values that may offer benefit to patients with high-risk 465 disease (either with hematuria at primary diagnosis or under surveillance).

One of the limitations of this study is that potential confounding factors such as clinical 467 treatments before the last recurrence were not available for all patients and thus were 468 not considered. Nevertheless, as shown in the initial study, prior treatment did not affect 469 the urinary peptidomic profiles (19). As another limitation of our study, follow-up data 470 were not accessible for all patients. Thus, correlation analysis of false positives cases 471 with later recurrences was not feasible. Therefore, no conclusion can be made on false-472 positives of BC-116 and BC-106 biomarker panels since they could be attributed to 473 early detection of subclinical recurrence that could not be detected by cystoscopy. This 474 has been previously described for other FDA-approved urinary biomarkers (37). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Prediction of muscle-invasive bladder cancer using urinary proteomics. Clinical 551 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 in C es he to ge ith . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The AUCs, 95% Cis, and P values are provided in the respective tables. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Global 503 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide 504 for 36 Cancers in 185 Countries

Cancer Facts & Figures

European 510 Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer

Carcinoma In Situ) -2019 Update

Can urinary biomarkers replace cystoscopy? 514

light cystoscopy for the detection of superficial papillary lesions in patients with 608 bladder cancer

Evaluation of the NMP22 610 BladderChek test for detecting bladder cancer: a systematic review and meta-611 analysis

Evaluation of 613 urovysion and cytology for bladder cancer detection: a study of 1835 paired urine 614 samples with clinical and histologic correlation

Reflex 617 UroVysion testing of bladder cancer surveillance patients with equivocal or negative 618 urine cytology: a prospective study with focus on the natural history of anticipatory 619 positive findings

Abbreviations: BC: bladder cancer; F: female

*Tumor grade and stage were determined according to WHO criteria (21) and TNM classification (22), 653 while the BC tumors were classified according to their risk of recurrence and progression into high, 654 intermediate, or low risk based on the EAU

Figure 2. A, ROC curve analysis for the urinary biomarker panel BC-116 performed in 726 the primary cohort. The AUC, 95% CI, and P value for the classification of the BC 727 patients are also provided in the table shown in Panel A. B-D, Classification scores 728

urothelial BC cases and the urologic controls, C) BC cases and controls according to 730 their TNM stage, and D) BC cases and controls considering their grade. The average 731 rank differences were significantly different